Form 4: Viking Therapeutics Director J Matthew Singleton Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director J Matthew Singleton exercised stock options and sold shares of Viking Therapeutics (VKTX) under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 19, 2024, J Matthew Singleton, a director of Viking Therapeutics, Inc. (VKTX), executed a transaction involving the company's stock.
• Singleton exercised stock options to acquire 16,000 shares of common stock at a price of $3.33 per share.
• Simultaneously, Singleton sold a total of 16,000 shares in multiple transactions at weighted average prices ranging from $60.0138 to $64.8798.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2024.
• Following these transactions, Singleton directly owns 9,500 shares of Viking Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-existing plan. There's no indication of positive or negative implications for the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard transaction, unless the volume or pattern deviates significantly from past behavior.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.

Key Dates